ASH 2021 – Myelofibrosis: Wrap-up

Early Treatment of Myelofibrosis with Ruxolitinib May Improve Overall Survival

Myelofibrosis is associated with poor overall survival and clinical outcomes. Treatment with ruxolitinib earlier in disease course shows promise for improving symptoms and overall survival. Read More ›

Page 2 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:

Learn more about our family of publications.

View Our Publications